At first, everyone just assumed there would be an advisory committee review.
As a first-in-class cannabinoid-1 receptor agonist—essentially an "anti-marijuana" effect in a pill—with a potential for broad off-label use, Sanofi-Aventis ...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?